Advertisement

Search Results

Advertisement



Your search for Clifford A. Hudis, MD, FACP,Clifford A. Hudis, MD, FACP matches 167 pages

Showing 101 - 150


health-care policy

ASCO Urges Administration to Provide Clear Affordable Care Act Guidance on Protecting Patient Access to Clinical Trials

ASCO has joined more than 50 other organizations in urging the Administration to issue regulations or guidance before January 2014 to ensure health plans implement an important provision of the Affordable Care Act that would remove a critical obstacle to patients interested in participating in...

issues in oncology
legislation

Legislative Endorsement Update From ASCO 

ASCO recently announced its endorsement of the Tobacco Tax Equity Act of 2014 (S. 194), which would close tax loopholes that allow tobacco companies to avoid the federal cigarette tax by making taxes on pipe tobacco equivalent to cigarette tobacco. “Raising tobacco taxes is one of the most...

issues in oncology

ASCO Launches New Site to Seek Feedback from Cancer Community on Clinical Practice Guidelines

ASCO has launched a new wiki site to engage the cancer community in its clinical practice guideline development process. The new site will provide oncologists, practitioners and patients with an opportunity to provide feedback or submit evidence on individual published guidelines and can be...

Communicating the Promise Science Offers to Society 

ASCO President Clifford Hudis, MD, FACP, will be serving during a particularly notable year: 2014, the Society’s 50th anniversary. This occasion brings with it much to reflect on, from the advances in the field of oncology to the growth of ASCO’s influence, but Dr. Hudis takes a moment to simply...

legislation

ASCO Releases Statement on the Impact of the Government Shutdown on Cancer Care 

All nonessential government services were suspended at midnight on October 1, 2013, after Congress failed to reach a budget compromise to keep the government funded before the start of the new fiscal year beginning on October 1, 2013. ASCO issued a statement in response to the government shutdown...

breast cancer

Pathologic Complete Response as a Test Bed for Novel Therapies: Proceed—With Caution! 

Pathologic complete response as assessed surgically after neoadjuvant treatment is being touted by some researchers as a stand-alone endpoint justifying early drug approval for breast cancer. They argue that it provides a more efficient means of testing the value of agents that might be useful in...

breast cancer
global cancer care

Zhe-Bin Liu, MD, PhD, of China Receives 2013 Long-Term International Fellowship in Breast Cancer

Zhe-Bin Liu, MD, PhD, of Shanghai Cancer Center, Fudan University, China, is the recipient of the 2013 Conquer Cancer Foundation of ASCO Long-Term International Fellowship (LIFe) in Breast Cancer, generously supported by The Breast Cancer Research Foundation. The LIFe provides early-career...

health-care policy
legislation

The Scientific Perils of Sequestration 

We are just 7 months into the $1 trillion in automatic federal budget spending cuts known as sequestration, and the impact on scientists in all areas of research is already so great, some say its full effects may be irreversible. The ASCO Post recently interviewed ASCO President Clifford A. Hudis, ...

palliative care

New Report Examines Trends in End-of-Life Care

Although fewer Medicare patients with cancer died in the hospital in 2010 than in the years 2003–2007, aggressive treatment continues at the end of life, according to a new report from the Dartmouth Atlas Project.1 The findings also show that a significant number of patients were likely to receive...

ASCO Announces Inaugural Class for Quality Training Program

For oncologists, continuous quality improvement is a key goal. We measure and assess the quality of care we deliver and constantly look for areas where we can do better,” said ASCO President Clifford A. Hudis, MD, FACP.  “ASCO’s Quality Training Program will guide oncology care providers in...

health-care policy

IOM Report Illuminates U.S. Cancer Care Crisis and Offers Framework for Change

In September, the Institute of Medicine (IOM) of the National Academies issued its report, Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis,1 published more than a decade after its first study on the quality of cancer care in the United States. The authors of the...

issues in oncology

ASCO Launches Formal Development of CancerLinQ™ System 

ASCO recently announced that it has initiated development of the full CancerLinQ™ system, a groundbreaking health information technology (HIT) initiative to achieve higher-quality, ­higher-value cancer care with better ­outcomes for patients. The announcement was made at a White House Office of...

issues in oncology

More Than 200 Practices Now QOPI® Certified for Delivering High-Quality Cancer Care

ASCO and its affiliate, the Quality Oncology Practice Initiative (QOPI®) Certification Program (QCP™), have announced that more than 200 practices have received certification. Since its start in 2010, the QOPI Certification Program has evaluated individual outpatient oncology practice performance...

health-care policy

Statement by ASCO President Clifford A. Hudis, MD, FACP,  on ACS Report

“The American Cancer Society [recently] issued a report showing a 20% decline in cancer death rates between 1991 and 2010, and estimating that 1.3 million deaths have been averted as a result of the decline.  “This is tremendous progress and a direct result of our nation’s commitment to cancer...

health-care policy

ASCO Statement on Annual Report to the Nation on the Status of Cancer 

Clifford A. Hudis, MD, FACP, President of ASCO, commented recently on the Annual Report to the Nation on the Status of Cancer, co-authored by the National Cancer Institute, the American Cancer Society, the Centers for Disease Control and Prevention, and the North American Association of Central...

issues in oncology
health-care policy

50th Anniversary of the First U.S. Surgeon General’s Report on Smoking and Health

“When the first Surgeon General’s Report was released in 1964, more than half of American men and over a third of women smoked and lung cancer had gone from an obscure disease to a leading cause of death. In issuing this pioneering report summarizing the known health risks of smoking, our nation’s...

Nearly 40 Practices Receive QOPI® Recertification for High-Quality Cancer Care

Nearly 40 practices have achieved certification through the Quality Oncology Practice Initiative (QOPI®) Certification Program (QCP™) for a second 3-year term. The QOPI Certification Program began certifying practices in 2010 and is now seeing the first wave of practices applying for a second term. ...

lung cancer

ASCO President Issues Statement on Major Decline in Lung Cancer

Editor’s note: The Centers for Disease Control and Prevention (CDC) recently issued a report on lung cancer incidence trends in the United States.1 According to the report, incidence rates for lung cancer have decreased between 2005 and 2009, the period evaluated. Lung cancer incidence has...

issues in oncology

ASCO Applauds CVS Caremark’s Move to Stop Selling Tobacco

CVS Caremark recently announced that it will stop selling cigarettes and other tobacco products at its more than 7,600 CVS/pharmacy stores across the United States by October 1, 2014, making CVS/pharmacy the first national pharmacy chain to take this step in support of the health and well-being of...

health-care policy

President Obama’s FY 2015 Budget Proposal

[On March 4, 2014], President Obama released his proposed budget for fiscal year 2015. Among several cost-cutting measures designed to preserve Medicare solvency is a proposal to reduce reimbursement for life-sustaining cancer drugs. Currently, reimbursement to physicians for “Part B” drugs is...

ASCO Holds Leadership Summit to Address Value in Cancer Care, Cost of Cancer Drugs and Technologies

ASCO convened a leadership summit in late January with pharmaceutical representatives, insurance payers, patient advocates, and physicians to initiate a dialogue on the challenge of defining value in cancer care. This meeting was held amid growing concerns about the sustainability of continued...

legislation
health-care policy

Greatly Frustrated by Congressional Failure to Act on Sustainable Growth Rate

The American Society of Clinical Oncology (ASCO) is deeply frustrated by the failure of Congress to permanently repeal the flawed sustainable growth rate (SGR) formula used to set Medicare physician payments and passage of the 17th patch to the system. ASCO and the entire physician community worked ...

health-care policy

ASCO Releases Its First-Ever Report on the State of Cancer Care in America

On March 11, ASCO released its first-ever comprehensive assessment of the daunting challenges facing America’s ability to continue to deliver high-quality care to all patients with cancer. ASCO President Clifford A. Hudis, MD, FACP, introduced the assessment at a Congressional news briefing in...

ASCO Cofounder Jane Cooke Wright, MD, Defied Racial/Gender Barriers and Helped Usher in the Modern Age of Chemotherapy

When Jane Cooke Wright, MD, met with six other oncologists at the Edgewater Beach Hotel in Chicago on April 9, 1964, to discuss the creation of American Society of Clinical Oncology, the first medical society dedicated to bringing patient-oriented issues to clinical oncology, the Civil Rights Act...

issues in oncology

Reflecting on the Past Year and Looking Ahead to the Next

On assuming the Presidency of ASCO a year ago, I recognized that one of our greatest challenges as a professional society is helping the American public understand the value of cancer research, especially now, when scientific advances are accelerating but resources are contracting. This is partly...

ASCO Through the Years: Past Presidents

This year ASCO celebrates it's 50th Anniversary. Here is a list of past ASCO Presidents over these 50 years: 2014-2015: Peter P. Yu, MD 2013-2014: Clifford A. Hudis, MD 2012-2013: Sandra M. Swain, MD, FACP 2011-2012: Michael P. Link, MD 2010-2011: George W. Sledge, Jr, MD 2009-2010: Douglas W....

Congress Celebrates 50 Years of ASCO: Special Order on House Floor Honors Society’s Mid-Century Anniversary

The U.S. House of Representatives recently held a Special Order in honor of the American Society of Clinical Oncology (ASCO) as it celebrates its 50th anniversary. During the event on the House floor, Members of Congress highlighted critical advancements in cancer care over the past 50 years and...

cost of care

Speaking Up Against High Cancer Drug Prices

Physicians have a duty to speak up against high cancer drug prices,” Hagop M. Kantarjian, MD, resolutely stated in an interview with The ASCO Post. “We should speak up because high drug prices are harming patients.” A leader in the effort to drive down the cost of drugs needed to treat patients...

ASCO Immediate Past President Hudis Urges Congress to Invest in Medical Research

In April, ASCO Immediate Past President Clifford A. Hudis, MD, FACP, urged Congress to recognize the need for further investment in medical research to protect this valuable infrastructure in testimony submitted to the U.S. Senate Committee on Appropriations. The testimony provided examples of how...

ASCO Takes Aim at the Link Between Obesity and Cancer

ASCO is stepping up its efforts to address the link between obesity and cancer—both as a leading cause of cancer and as a complicating factor for treatment. In recent years, research has demonstrated that a growing number of cancers are linked to obesity, and public health researchers predict that...

Expert Point of View: Clifford A. Hudis, MD, FACP

“To our surprise, obesity had a negative prognostic effect on premenopausal patients with breast cancer but not on those who were postmenopausal. We need to consider these findings in the context of results from other data sources that suggest that obesity remains a negative prognostic feature in...

Expert Point of View: Peter P. Yu, MD

Discussing the study on immediate vs deferred androgen deprivation therapy in the setting of prostate cancer with prostate-specific antigen (PSA)-only relapse, ASCO President Peter P. Yu, MD, noted that more than 60,000 men each year will face the dilemma of when to start androgen deprivation...

prostate cancer

‘Unprecedented’ Survival Benefit in Prostate Cancer With Addition of Docetaxel to Hormone Therapy

Adding docetaxel to standard androgen ablation therapy (ie, testosterone suppression) extended survival by more than 1 year in men with newly diagnosed metastatic hormone-sensitive prostate cancer in the phase III E3805 trial, funded by the National Institutes of Health. As reported at the ASCO...

Videos Tell Stories of 50 Years of Progress Against Cancer

Nearly 3 years ago, ASCO launched CancerProgress.Net to mark the 40th anniversary of the signing of the U.S. National Cancer Act, which led to major new investments in cancer research and significant increases in cancer survival. The site provides a dynamic and interactive history of progress...

colorectal cancer

Combined With Chemotherapy, Cetuximab and Bevacizumab Found Comparable for First-Line Metastatic Colorectal Cancer Treatment

Call it a draw: Cetuximab (Erbitux), an EGFR inhibitor,  and bevacizumab (Avastin), a VEGF inhibitor, confer comparable benefits as first-line treatment with chemotherapy for metastatic colorectal cancer, according to the phase III Cancer and Leukemia Group B (CALGB)/Southwest Oncology Group (SWOG) ...

breast cancer

Exemestane/Ovarian Suppression Reduces Recurrence vs Tamoxifen/Ovarian Suppression in Premenopausal Breast Cancer

A joint analysis of two important phase III clinical trials—TEXT (Tamoxifen and Exemestane Trial) and SOFT (Suppression of Ovarian Function Trial)—showed that exemestane plus ovarian function suppression was superior to tamoxifen plus ovarian suppression in preventing recurrence in premenopausal...

issues in oncology

Navigating Cancer in the Era of Personalized Medicine: Rev 2014 Explores Emerging Issues, Ideas for Action

Diagnosed with stage IV non–small cell lung cancer in 2011, Stephen Wright turned to patient support groups where he learned about the anaplastic lymphoma kinase (ALK) mutation and a new drug that targeted it, crizotinib (Xalkori). He asked—then insisted—that he be tested for the mutation. He found ...

cost of care

Federally Funded Trials Praised—and Underfunded

All four studies presented at the 2014 ASCO Annual Meeting Plenary Session were at least partially funded by federal dollars, bringing long overdue attention to the value of federally supported cancer research. Perhaps because of this high visibility, ASCO leaders took to the soapbox to sound the...

issues in oncology
cost of care

Stakeholders Are Uniting Around Value in Cancer Care

Judging from its visibility at the 2014 ASCO Annual Meeting, the concept of “value” in cancer care has reached critical mass. “ASCO is leading this difficult discussion on value in cancer care. This had to happen,” said ­Clifford A. Hudis, MD, FACP, Immediate Past President of ASCO and Chief of the ...

issues in oncology

Take-Home Messages From ASCO's Immediate Past President

The ASCO Post recently spoke with ASCO Immediate Past President Clifford A. Hudis, MD, FACP, about his term as ASCO President. Dr. Hudis discussed his thoughts on ASCO today and shared his perspective on a number of important issues in oncology, including value in cancer care, big data, and more....

issues in oncology

Center for Medicare and Medicaid Services Approves QOPI® as Pathway for Federally Required Quality Reporting

The Centers for Medicare and Medicaid Services (CMS) has approved ASCO’s Quality Oncology Practice Initiative (QOPI®) as a pathway for oncologists to meet the agency’s quality reporting requirements. Starting in the fall of 2014, oncology practices registered with QOPI will have the opportunity to...

A World Free From the Fear of Cancer—Is It Possible?

By every definition, ASCO’s 50th Annual Meeting was a huge success. The halls were buzzing as nearly 35,000 attendees shared excitement about cancer research.   This was a banner year for federally funded clinical trials—all four of the abstracts selected for ASCO’s Plenary Session were backed by...

issues in oncology

ASCO Calls for New Action to Address Obesity and Cancer

ASCO has called for increased education, research, and advocacy to reduce the toll of obesity, both as a leading cause of cancer and a complication in the care of patients with cancer. The Society’s recommendations outline four critical priorities, including increased education and awareness about...

breast cancer

Guidelines and Care: What Comes Next?

The goal of clinical, translational, and basic research is, in the end, the betterment of life on earth. Advances in basic and clinical science ultimately should lead to information that, in turn, enables clinicians to make better treatment decisions for individual patients in order to improve...

2014 Featured Columnists

The ASCO Post wishes to acknowledge and thank all contributors to the publication during 2014. Here we recognize those who shared their personal thoughts in our Op-Ed department. If you are interested in contributing to The ASCO Post in 2015, write to editor@ASCOPost.com.   Robert Peter Gale, MD,...

breast cancer

Enzalutamide Shows Encouraging Activity in Triple‑Negative Breast Cancer

The androgen receptor inhibitor enzalutamide (Xtandi) showed encouraging activity as a single agent in advanced triple-negative breast cancer patients expressing the androgen receptor, according to an international study presented at the 2014 San Antonio Breast Cancer Symposium.1 Enzalutamide...

Researchers and Scientists Honored for Improving Cancer Prevention, Treatment, and Patient Care

The ASCO Special Awards recognize the dedication and significant contributions of researchers, patient advocates, and leaders of the global oncology community to enhancing cancer prevention, treatment, and patient care. Among this year’s awardees are an international leader in geriatric oncology...

issues in oncology

Precision Medicine Trials Bring Targeted Treatments to More Patients

At the 2015 ASCO Annual Meeting, both ASCO and the National Cancer Institute (NCI) unveiled details of new precision medicine trials that will greatly expand the number of patients with cancer who are benefiting from targeted agents. The trials will match a patient’s tumor molecular profile with an ...

issues in oncology

Past President of ASCO Takes on New Role at Memorial Sloan Kettering Cancer Center to Improve Patient Care and Public Health

In June, Memorial Sloan Kettering Cancer Center (Memorial) in New York announced it had appointed ­Clifford A. Hudis, MD, FACP, Chief of Breast Medicine Service, to a newly created position of Vice President for Government Relations and Chief Advocacy Officer. In addition to his new role, Dr. Hudis ...

issues in oncology

TAPUR: ASCO’s First Clinical Trial Addresses Critical Gaps in Understanding of and Access to Targeted Therapies

ASCO is preparing to expand the boundaries of precision medicine with the launch of its first clinical trial. At a press briefing during the 2015 ASCO Annual Meeting, the Society formally announced its plans for the Targeted Agent and Profiling Utilization Registry (TAPUR) study. At a time when...

Advertisement

Advertisement



Advertisement